Compare · GLP-1 agonist
Ecnoglutide vs Orforglipron
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Orforglipron | |
|---|---|---|
| Evidence | Preliminary human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (development code XW003) is an injectable drug for type 2 diabetes and weight loss that belongs to the same broad GLP-1 receptor agonist family as semaglutide. It stands out for two reasons: its developer engineered it to be "cAMP-biased," a real and characterized pharmacological…
Orforglipron
Orforglipron (brand name Foundayo) is a GLP-1 receptor agonist — the same drug class as semaglutide and tirzepatide — but with one defining difference: it is a small molecule, not a peptide, and it is taken as a once-daily pill rather than an injection. In April 2026 the FDA approved it for chronic…